Drugs Made In America Acquisition II Corp.

Listed Company

DMIICIK 0002040475NasdaqNon-AcceleratedSmaller ReportingEmerging GrowthBlank ChecksFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$4.19M

Total Assets

$504.96M

Equity

$-17.77M

Shares Out

63.70M

Op. Cash Flow

$-1.02M

Business

Drugs Made In America Acquisition II Corp. is a publicly listed company in Blank Checks. Common stock trades on Nasdaq under the ticker DMII.

Auto-generated from company profile

Year Ended · In millions, except per-share amounts

Concept	Trend	FY 2025 2025-12-31
General and administrative costs		488,385
Total operating expenses		488,385
Loss from operations		−488,385
Interest earned on cash and investments held in Trust Account		5
Gain on extinguishment of over-allotment option liability		553,748
Provision for credit losses		−812,113
Total other income		5
Net income (loss)		4

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2024 2024-08-31
Cash	223	17,035	—
Due from Sponsor, net of reserve for credit losses of $812,113	—	—	—
Prepaid expenses	25,814	42,580	—
Total Current Assets	26,037	59,615	—
Deferred offering costs	—	78,449	—
Cash and investments held in Trust Account	505	—	—
Total Non-current Assets	505	78,449	—
TOTAL ASSETS	505	138,064	—
Accounts payable	99,359	—	—
Accrued expenses	88,343	—	—
Accrued offering costs	113,162	4,683	—
Promissory Note Related Party	—	250,100	—
Total Current Liabilities	300,864	254,783	—
Deferred underwriting fee payable	18	—	—
Total Non-current Liabilities	18	—	—
TOTAL LIABILITIES	18	254,783	—
Commitments and Contingencies (Note 6)	—	—	—
Ordinary shares subject to possible redemption, 50,000,000 shares at redemption value of $10.00 and $0 per share as of December 31, 2025 and 2024, respectively	505	—	—
Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding as of December 31, 2025 and 2024	—	—	—
Ordinary shares, $0.0001 par value; 220,000,000 shares authorized; [13,700,000] and 14,375,000 shares issued and outstanding, excluding 50,000,000 and 0 shares subject to redemption as of December 31, 2025 and 2024, respectively(1)(2)	1,369	1,437	—
Additional paid-in capital	—	33,563	—
Accumulated deficit	−18	−151,719	—
Total Shareholders Deficit	−18	−116,719	—
TOTAL LIABILITIES, ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION, AND SHAREHOLDERS DEFICIT	505	138,064	—

Year Ended · In millions, except per-share amounts

Concept	Trend	FY 2025 2025-12-31
Payment of operating costs through promissory note		77,799
Prepaid expenses		16,766
Due from Sponsor		−812,113
Accounts payable		99,359
Accrued expenses		88,343
Net cash used in operating activities		−1
Investment of cash into Trust Account		−500
Net cash used in investing activities		−500
Proceeds from sale of Units, net of underwriting discounts paid		490
Proceeds from issuance of founder shares to Sponsor		—
Proceeds from promissory note - related party		—
Proceeds from sale of Private Placement Units		12
Repayment of promissory note - related party		−533,781
Payment of offering costs		−464,800
Net cash provided by financing activities		501
Net Change in Cash		−16,812
Offering costs included in accrued offering costs		108,479
Deferred offering costs paid through promissory note related party		205,881
Accretion and remeasurement of redeemable ordinary shares to redemption value		44
Deferred underwriting fee payable		18
Deferred offering costs for issuance of Public Units		857,609
Fair value of rights included in Public Units		10

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro